.Pharmacolibrary.Drugs.V_Various.V09G_CardiovascularSystem.V09GX02_Indium111inImciromab.Indium111inImciromab .Pharmacolibrary.Drugs.V_Various.V09G_CardiovascularSystem.V09GX02_Indium111inImciromab.Indium111inImciromab| name: | Indium111inImciromab | |
| ATC code: | V09GX02 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 1 | mg |
| volume of distribution: | 4.5 | L |
| clearance: | 90 | mL/h/kg |
| other parameters in model implementation | ||
Indium (111In) imciromab, also known as In-111 labeled antimyosin Fab (Myoscint), is a murine monoclonal antibody fragment (Fab) labeled with radioactive indium-111. It was historically used as a radiopharmaceutical agent to detect myocardial necrosis by targeting cardiac myosin exposed in damaged heart tissue. Due to immunogenicity and other clinical issues, it is no longer widely approved or used.
Pharmacokinetic parameters estimated for adult patients based on sparse literature and radiopharmaceutical clinical dosing.